Electronic informed consent, or eConsent, replaces a paper consent form with a digital process, but the regulatory bar it has to clear is the same one paper consent always had to clear: the participant has to actually understand what they’re agreeing to. The FDA’s joint guidance with HHS’s Office for Human Research Protections, finalized in December 2016, sets out recommendations for using electronic systems to obtain informed consent in both FDA-regulated and HHS-regulated human subject research.
The appeal of eConsent is obvious: less paper, faster enrollment, and formats like embedded video or interactive comprehension checks that a static PDF can’t offer. The harder part, and the part sponsors and IRBs actually scrutinize, is whether the electronic process still does what informed consent is supposed to do: present the right information to the right participant, confirm they understood it, and produce a record that holds up under review.
Where Conditional Logic Actually Helps
A single, flat consent form struggles with trials that have multiple arms, sub-studies, or eligibility-dependent procedures, because either every participant sees content that doesn’t apply to them, or separate paper forms have to be maintained for each variant. Conditional logic addresses this directly: a participant’s answers to eligibility or arm-assignment questions can determine which consent content they see next, so someone consenting to a specific sub-study sees the language relevant to that sub-study, not a generic document covering every possible arm.
This matters for regulatory review as much as participant experience. An IRB reviewing an eConsent process wants to see that participants are being shown the correct, complete information for their specific study path, not a one-size-fits-all document with irrelevant sections they’re expected to skip past.
What Regulatory Review Actually Looks For
Beyond content accuracy, reviewers evaluating an eConsent process generally look for a few specific things:
- A clear record of what version of the consent document a specific participant saw and signed, given that consent language can be amended mid-study
- A mechanism to confirm comprehension, whether through embedded questions or a structured walkthrough, rather than just a signature at the bottom of a long document
- A complete, timestamped audit trail showing when consent was given, by whom, and under what version of the form
None of this is exotic from a technical standpoint. These are the same requirements that apply to any regulated data collection process: version control, structured logic, and an audit trail that can answer specific questions after the fact. What makes eConsent distinct is the stakes: a consent record that can’t be defended under scrutiny puts the validity of trial data at risk, not just a single form submission.
Where FormAssembly Fits
FormAssembly’s conditional logic lets a consent workflow branch based on eligibility, study arm, or sub-study assignment, so participants see the consent content relevant to their specific path rather than a generic document. E-signature collection captures a legally defensible signature tied to the exact version of the consent form presented, and every submission is preserved in a complete, timestamped audit trail that supports the documentation IRBs and sponsors review.
For organizations running trials across healthcare settings, that combination of conditional routing, defensible signatures, and full audit history is what lets an eConsent process meet the same bar paper consent has always had to meet, without reverting to a one-size-fits-all form.
Want to see conditional logic in action?
Book a personalized demo today or request a free trial of the platform.
